New Phase 3 clinical trials confirm that increasing weekly doses of semaglutide to 7.2 mg significantly enhances weight loss and metabolic health benefits in adults with obesity, with or without type 2 diabetes. These pivotal studies reinforce the dose-response relationship and safety profile of this glucagon-like peptide-1 receptor agonist, consolidating its role in obesity management protocols internationally.